Philippe L. Bedard

Philippe L. Bedard, MD, FRCPC is a Senior Medical Oncologist and Co-Lead of the Drug Development Program at Princess Margaret Cancer Centre in Toronto, where he holds a full professorship at the University of Toronto. He is internationally recognized for contributions to PD-L1 assay standardization through the Blueprint PD-L1 Harmonization Project, which rigorously compared the analytical performance and clinical concordance of four companion diagnostic PD-L1 immunohistochemistry assays (22C3, 28-8, SP142, SP263) across NSCLC and other tumor types. Bedard's Blueprint analyses—published in high-impact journals—provided the evidence base for regulatory decisions on PD-L1 assay interchangeability and remain a cornerstone reference for clinical pathology practice. He has also been a leader in basket trial design for biomarker-selected populations and in developing ctDNA-based response monitoring strategies for early drug development. His work bridging biomarker science and clinical trial design has influenced the architecture of precision oncology programs globally.